These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
178 related items for PubMed ID: 3097261
1. Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study. Konradi C, Riederer P, Youdim MB. J Neural Transm Suppl; 1986; 22():61-73. PubMed ID: 3097261 [Abstract] [Full Text] [Related]
2. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Löscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G. J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835 [Abstract] [Full Text] [Related]
3. Improvement of mouse brain mitochondrial function after deprenyl treatment. Czerniczyniec A, Bustamante J, Lores-Arnaiz S. Neuroscience; 2007 Jan 19; 144(2):685-93. PubMed ID: 17084986 [Abstract] [Full Text] [Related]
4. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. Bour S, Iglesias-Osma MC, Marti L, Duro P, Garcia-Barrado MJ, Pastor MF, Prévot D, Visentin V, Valet P, Moratinos J, Carpéné C. Eur J Pharmacol; 2006 Dec 15; 552(1-3):20-30. PubMed ID: 17056035 [Abstract] [Full Text] [Related]
5. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity]. Severina IS, Klimova GI, Nersisian AA. Biokhimiia; 1981 Nov 15; 46(11):2043-55. PubMed ID: 6797482 [Abstract] [Full Text] [Related]
10. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, Oikonen V, Sipilä H, Ruokoniemi P, Virtanen K, Scheinin M, Rinne JO. Clin Pharmacol Ther; 2009 May 15; 85(5):506-12. PubMed ID: 19129751 [Abstract] [Full Text] [Related]
13. Developmental aspects of the monoamine-degrading enzyme monoamine oxidase. Strolin Benedetti M, Dostert P, Tipton KF. Dev Pharmacol Ther; 1992 May 15; 18(3-4):191-200. PubMed ID: 1306808 [Abstract] [Full Text] [Related]
14. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease. Youdim MB. J Neural Transm Suppl; 1986 May 15; 22():91-105. PubMed ID: 3097263 [Abstract] [Full Text] [Related]
19. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MB. Adv Neurol; 1987 May 15; 45():111-8. PubMed ID: 3030067 [Abstract] [Full Text] [Related]
20. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Hauptmann N, Grimsby J, Shih JC, Cadenas E. Arch Biochem Biophys; 1996 Nov 15; 335(2):295-304. PubMed ID: 8914926 [Abstract] [Full Text] [Related] Page: [Next] [New Search]